SCHEMBL24142953

SCHEMBL24142953

NCCc1cn(Cc2ccccc2Br)c2cc(-c3ccncc3)ccc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.47
▸ NR1D1 P20393 6/20 0.42
▸ FNTA P49354 1/20 0.42
▸ FNTB P49356 1/20 0.42
▸ TAAR1 Q96RJ0 1/20 0.41
▸ HTR6 P50406 3/20 0.40
▸ EGFR P00533 1/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ FLT4 P35916 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ HTR2A P28223 1/20 0.36
▸ SERPINE1 P05121 1/20 0.34
▸ CHEK1 O14757 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ AKR1A1 P14550 1/20 0.33
▸ AKR1B1 P15121 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24143557 0.88 CYP19A1 (0.45) CYP19A1NR1D1TAAR1HTR6EGFR
SCHEMBL24144070 0.85 HTR6 (0.54) CYP19A1NR1D1HTR6EGFRIGF1R
SCHEMBL24144383 0.83 CYP19A1 (0.49) CYP19A1NR1D1FNTAFNTBTAAR1
SCHEMBL24143540 0.80 NR1D1 (0.42) NR1D1HTR6HTR2ASERPINE1CHEK1
SCHEMBL24143743 0.80 NR1D1 (0.50) CYP19A1NR1D1HTR6HTR2ACHEK1
SCHEMBL24142882 0.80 HTR6 (0.44) NR1D1HTR6EGFRIGF1RFLT4
SCHEMBL28811759 0.79 HTR6 (0.59) CYP19A1FNTAFNTBTAAR1HTR6
SCHEMBL24143548 0.79 NFATC1 (0.50) CYP19A1NR1D1HTR6EGFRIGF1R
SCHEMBL24144386 0.78 LMNA (0.45) NR1D1TAAR1HTR6EGFRIGF1R
SCHEMBL24144502 0.78 CYP19A1 (0.47) CYP19A1NR1D1TAAR1HTR6EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021263278-A1 REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2021-12-30 — — WO disclosed
Send feedback